AIM: The goal of this study was to semiquantitatively detect presence of cancer stem cells markers CD44 and CD133 in immunohistochemically stained paired samples of colorectal cancer (CRC) and colorectal liver metastases (CLM). Level of staining intensity was compared to clinical and pathological characteristics of tumors with the aim to identify impact of CD44 or CD133 expression on tumor behavior. PATIENTS AND METHODS: Formalin fixed paraffin embedded samples from 94 patients with colorectal tumor and liver metastases were collected at Sikl's Department of Pathology. Samples were stained by antibodies against CD44 and CD133. Presence and intensity of staining was assessed semiquantitatively by three trained researchers. RESULTS: Patients with higher level of CD133 staining in CRC had longer disease free interval (Cox-Mantel P = 0.0244), whereas we found no relation between CD44 expression and overall survival or disease free interval. CD133 expression in CRC and CLM differed based on CRC grading; in case of CD44 we found differences in staining intensity in individual stages of tumor lymph node invasion. CONCLUSION: Effect of cancer stem cell markers on prognosis of colorectal cancer can vary depending on pathological classification of tumor, and we have shown that CD133, generally considered to be a negative marker, can bear also clinically positive prognostic information in group of patients with colorectal liver metastases.

Biomedical Center Faculty of Medicine in Pilsen Charles University Prague Husova 3 306 05 Pilsen Czech Republic

Biomedical Center Faculty of Medicine in Pilsen Charles University Prague Husova 3 306 05 Pilsen Czech Republic ; Department of Histology and Embryology Faculty of Medicine in Pilsen Charles University Prague Karlovarská 48 301 00 Pilsen Czech Republic

Biomedical Center Faculty of Medicine in Pilsen Charles University Prague Husova 3 306 05 Pilsen Czech Republic ; Department of Surgery Medical School and Teaching Hospital Pilsen Charles University Prague Alej Svobody 80 304 60 Pilsen Czech Republic

Department of Histology and Embryology Faculty of Medicine in Pilsen Charles University Prague Karlovarská 48 301 00 Pilsen Czech Republic

Department of Surgery Medical School and Teaching Hospital Pilsen Charles University Prague Alej Svobody 80 304 60 Pilsen Czech Republic

Sikl's Department of Pathology Medical School and Teaching Hospital Pilsen Charles University Prague Dr E Benese 13 305 99 Pilsen Czech Republic

Zobrazit více v PubMed

Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine. 1997;3(7):730–737. PubMed

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(7):3983–3988. PubMed PMC

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research. 2005;65(23):10946–10951. PubMed

Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–115. PubMed

O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–110. PubMed

Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Research. 2007;67(3):1030–1037. PubMed

Gottschling S, Schnabel PA, Herth FJF, Herpel E. Are we missing the target? Cancer stem cells and drug resistance in non-small cell lung cancer. Cancer Genomics Proteomics. 2012;9(5):275–286. PubMed

Aguilar-Gallardo C, Simón C. Cells, stem cells, and cancer stem cells. Seminars in Reproductive Medicine. 2013;31(1):5–13. PubMed

Ishii H, Iwatsuki M, Ieta K, et al. Cancer stem cells and chemoradiation resistance. Cancer Science. 2008;99(10):1871–1877. PubMed PMC

Friedman MD, Jeevan DS, Tobias M, Murali R, Jhanwar-Uniyal M. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Oncology Reports. 2013;30(4):1645–1650. PubMed

Dalerba P, Dylla SJ, Park I-K, et al. Phenotypic characterization of human colorectal cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(24):10158–10163. PubMed PMC

Vermeulen L, Todaro M, De Sousa Mello F, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(36):13427–13432. PubMed PMC

Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Research. 2009;69(8):3382–3389. PubMed PMC

Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. Journal of Clinical Investigation. 2008;118(6):2111–2120. PubMed PMC

Liska V, Vycital O, Daum O, et al. Infiltration of colorectal carcinoma by S100+ dendritic cells and CD57+ lymphocytes as independent prognostic factors after radical surgical treatment. Anticancer Research. 2012;32(5):2129–2132. PubMed

Ren F, Sheng WQ, Du X. CD133: a cancer stem cells marker, is used in colorectal cancers. World Journal of Gastroenterology. 2013;19(17):2603–2611. PubMed PMC

Galizia G, Gemei M, Del Vecchio L, et al. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Archives of Surgery. 2012;147(1):18–24. PubMed

Li XD, Ji M, Wu J, Jiang JT, Wu CP. Clinical significance of CD44 variants expression in colorectal cancer. Tumori. 2013;99(1):88–92. PubMed

Langan RC, Mullinax JE, Ray S, et al. A pilot study assessing the potential role of non-CD133 colorectal cancer stem cells as biomarkers. Journal of Cancer. 2012;3:231–240. PubMed PMC

Kemper K, Sprick MR, De Bree M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Research. 2010;70(2):719–729. PubMed

Liao Y, Hu X, Huang X, He C. Quantitative analyses of CD133 expression facilitate researches on tumor stem cells. Biological and Pharmaceutical Bulletin. 2010;33(5):738–742. PubMed

Chen S, Song X, Chen Z, et al. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS ONE. 2013;8(2)e56380 PubMed PMC

Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. British Journal of Cancer. 2008;99(8):1285–1289. PubMed PMC

Gharagozloo M, Mirzaei HR, Bagherpour B, et al. Cell cycle analysis of the CD133+ and CD133− cells isolated from human colorectal cancer. Journal of Cancer Research and Therapeutics. 2012;8(3):399–403. PubMed

Altered Expression of MBNL Family of Alternative Splicing Factors in Colorectal Cancer